Genvax Technologies Closes Series Seed Plus Round; Dr. Lucas Hunmer Joins as Chief Scienfic Officer
United Animal Health and Current Investors Support Genvax’s Paradigm Shift in Vaccine Response to Infectious Animal Diseases
Ames, IA, February 3, 2025 — Genvax Technologies, a startup dedicated to bringing advances in RNA vaccine production to animal health, announced today it has closed its Series Seed Plus funding. This pivotal funding will accelerate the company's path toward USDA approval of its vaccines, enabling rapid response to foreign animal disease outbreaks and improving livestock health and profitability.
In addition, Genvax welcomed Dr. Lucas Huntimer as Chief Scientific Officer to lead innovation and drive their product pipeline forward. Dr. Huntimer brings decades of expertise in vaccine development, regulatory strategy, and sustainable solutions through leadership roles at Novartis, Elanco, and Rumin8. A Ph.D. graduate in Immunobiology from Iowa State University, Dr. Huntimer has consistently focused on advancing vaccine efficacy and managing complex R&D portfolios.
Read More
Originaly published by Genvax Technologies in February 2025.